| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.03 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.03 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.059 | 0.03 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.03 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.04 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.073 | 0.04 |